2-(2-Amino-Phenyl)-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester

In multi-kilogram campaigns for c-Met/ALK dual inhibitors, 2-(2-amino-phenyl)-pyrrolidine-1-carboxylic acid tert-butyl ester functions as the arylpyrrolidine donor in late-stage Buchwald–Hartwig amination sequences. A representative production protocol charges the Boc-protected aniline at 1.02–1.15 molar equivalents relative to a 2,6-dichloro-3-fluorophenyl electrophile in toluene at reflux, with Pd₂(dba)₃ (0.5 mol%) and Xantphos (1.0 mol%). Process-scale deviations observed in 500 L glass-lined reactors include temporary emulsion formation during aqueous carbonate quench, resolved by passing the biphasic mixture through a 0.5 µm in-line Teflon mesh coalescer prior to gravity separation. The free amine is generated via TFA-mediated deprotection in DCM at 0–5 °C, telescoped into HCl salt formation without isolation of the neutral amine, an operation that eliminates a hygroscopic intermediate prone to hydrate formation at ambient RH > 55%. The resulting 2-(2-aminophenyl)pyrrolidine dihydrochloride is then coupled with a pyrazole boronate under Suzuki–Miyaura conditions (Pd(PPh₃)₄, Na₂CO₃, DME/H₂O 3:1). Terminal molecules include crizotinib, its besylate and succinate co-crystals, and the benzenesulfonate solid form for inhalation delivery. Regulatory oversight in this segment is governed by ICH Q7 for active pharmaceutical ingredient starting materials, with the Boc intermediate typically designated at GMP Step 2 or 3 depending on the applicant’s Drug Master File (DMF) submission under FDA 21 CFR 314.420. Residual palladium and boron must meet Ph. Eur. 2.4.20 / USP <232> limits; typical campaign data from a CMO in Visakhapatnam show Pd content after charcoal filtration and Celite® pad recirculation of 0.8–1.2 µg/g per batch.

Chiral P,N-Ligand Libraries Assembled from a Common Pyrrolidine-Aniline Subunit

The distinct steric environment imposed by the 2-(2-aminophenyl) substituent on the pyrrolidine ring enables diastereomeric phosphoramidite and phosphine-oxazoline ligand synthesis with high modularity. In a typical ligand preparation, the Boc-protected compound is subjected to lithium–halogen exchange with n-BuLi (2.2 equiv) in THF at −78 °C, followed by quenching with chlorodiphenylphosphine to yield a P,N-bidentate precursor. The Boc carbamate remains intact throughout the phosphination step, a deliberate strategy that prevents phosphine oxide formation during aqueous work-up. Deprotection with HCl in cyclopentyl methyl ether yields the phosphino-aniline hydrochloride as a non-hygroscopic crystalline solid, which can be stored under nitrogen at 2–8 °C for up to 12 months without detectable oxidation by ³¹P NMR. The resulting ligands, evaluated in Rh-catalyzed asymmetric hydrogenation of methyl (Z)-2-acetamidocinnamate, deliver enantiomeric excesses above 94% at 10 bar H₂ and 25 °C, as measured by chiral HPLC (Chiralpak IA, hexane/ethanol 90:10). A significant process bottleneck arises during the purification of the diastereomeric phosphine intermediates: column chromatography on silica gel with ethyl acetate/hexane 1:4 generates back-pressure spikes exceeding 40 bar on a 15 cm ID dynamic axial compression column when loading exceeds 2.5 wt% crude per gram of silica. Operators in pilot facilities mitigate this by pre-adsorbing the crude onto Celite® (1:2 w/w) and employing a step gradient of 2% MTBE in heptane. Compliance with REACH Annex XVII restrictions on diphenylphosphine derivatives is obligatory, and waste streams containing chlorophosphines must be quenched with aqueous sodium hypochlorite (10% active chlorine) before disposal. The terminal materials manufactured under this methodology serve as chiral inducers in the production of the CGRP receptor antagonist ubrogepant and the JAK inhibitor deucravacitinib, where the pyrrolidine scaffold contributes to P-gp efflux ratio reduction.

In the preparation of covalent inhibitor warheads for BTK and FGFR targets, the Boc-aminophenylpyrrolidine serves as the nucleophilic partner in acrylamide formation. A 50 kg campaign executed in a cGMP-compliant facility in Hyderabad utilized the compound at 0.98–1.00 equivalents with acryloyl chloride (1.05 equiv) in THF containing triethylamine (1.2 equiv) at −15 to −10 °C. Exotherm control in this Schotten–Baumann-type acylation required a jacket temperature of −25 °C with brine circulation at 120 L/min to maintain internal temperature below −8 °C during the 45-minute addition. The formation of a transient gel phase occurred when the reaction mixture was allowed to warm to 2 °C before the quench, traced to insoluble triethylammonium chloride co-crystallizing with THF; this was resolved by switching to N-methylmorpholine (1.1 equiv) in subsequent batches, which kept the hydrochloride salt dissolved. The crude N-acryloyl intermediate was carried forward without chromatography into a Boc deprotection with 5.0 M HCl in 2-propanol, affording the anilinium chloride in 92% yield over two steps. The resultant acrylamide fragment is employed in the manufacture of zanubrutinib and rilzabrutinib, where the pyrrolidine ring provides a torsional angle of approximately 65° between the phenyl ring and the acrylamide Michael acceptor, as determined by single-crystal X-ray diffraction, a geometry critical for selective Cys481 engagement. ICH Q3A impurity thresholds for the Boc intermediate are set at reporting level 0.05% and identification level 0.10%; a process-related impurity, the dimeric urea formed via adventitious carbodiimide coupling during extended storage at ambient temperature, is controlled to below 0.08% by maintaining the solid product under nitrogen at −20 ± 5 °C.

How Does the Pyrrolidine Conformation Influence Cereblon Ligand Activity?

The Boc-protected 2-(2-aminophenyl)pyrrolidine is a core structural element in heterobifunctional PROTAC linkers that connect a cereblon-binding immunomodulatory moiety to a target protein ligand. The ortho-substituted aniline provides a vector for amide bond formation with a glutarimide-based carboxylic acid, while the pyrrolidine nitrogen—after Boc removal—serves as a secondary attachment point for polyethylene glycol spacers. Process chemists at a CDMO in Shanghai established a one-pot deprotection-acylation sequence using TFA/DCM 1:1 (v/v) at 20 °C for 30 minutes, followed by evaporation and direct coupling with Fmoc-8-amino-3,6-dioxaoctanoic acid using HATU (1.15 equiv) and DIPEA (3.0 equiv) in DMF. The crude Fmoc-protected intermediate precipitated upon addition of water (10 volumes) and was isolated by centrifuge filtration (filter cloth pore size 10 µm) with a purity of 96.2% by HPLC (area%, 254 nm). The Fmoc group was subsequently cleaved with piperidine/DMF 20% to liberate the primary amine, enabling divergent functionalization. This strategy undergirds the preclinical supply of ARV-471 and related ER-targeting PROTAC molecules. The critical quality attribute for the Boc intermediate in this application is residual TFA content, which must be below 50 ppm by ion chromatography, as residual trifluoroacetate forms a persistent complex with the deprotected pyrrolidine nitrogen that attenuates the acylation rate by 40%, as measured by in situ ReactIR monitoring of the isocyanate peak at 2270 cm⁻¹. The operation is conducted under ISO 8 cleanroom conditions, and all solvents used in the final coupling step are controlled for peroxides per Ph. Eur. 2.5.5 Method A. Terminal dosage forms include orally bioavailable chimeric degraders with molecular weights in the 800–1100 Da range, for which the Boc-aminophenylpyrrolidine contributes roughly 21–24% of the total molecular framework.

When Ortho-Iodination Precedes Heterocycle Installation

An alternative synthetic trajectory for ROS1/TRK inhibitors departs from the standard aniline reactivity by performing a directed ortho-metalation–iodination on the Boc-protected scaffold prior to cross-coupling. The free amine of the phenyl ring is first transiently protected as the pivalamide by treatment with pivaloyl chloride (1.05 equiv) and pyridine in DCM. Subsequent treatment with n-BuLi (2.4 equiv) and TMEDA (2.5 equiv) at −40 °C generates the ortho-lithiated species, which is quenched with iodine (2.2 equiv) in THF to furnish the 2-iodo-6-pivalamidophenylpyrrolidine derivative. The pivalamide directing group is cleaved under acidic methanolysis (HCl/MeOH, 65 °C, 8 h), regenerating the free aniline. This ortho-iodo intermediate is then engaged in Sonogashira coupling with trimethylsilylacetylene, followed by desilylation (TBAF, THF, 0 °C) to yield an ethynyl intermediate that serves as a key building block for entrectinib and its monomesylate salt. The Boc group remains intact through all these transformations, ensuring crystalline intermediates at each stage and eliminating chromatographic purification for the iodo compound, which crystallizes from heptane/ethyl acetate 5:1 with a purity of 99.8% (HPLC). Scale-up at a kilo lab in Penzberg using a 20 L jacketed reactor equipped with a retreat-curve impeller encountered a yield drop from 78% to 61% when the lithiation temperature drifted above −30 °C, attributable to competitive deprotonation at the pyrrolidine C-5 position leading to ring-opening byproducts. Mitigation required a cascaded cryogenic setup with an external liquid nitrogen evaporator capable of delivering −45 °C silicone oil to the jacket at a flow rate of 30 L/min. Finished drug substance specifications for entrectinib under ICH Q6A require the Boc intermediate-derived impurities M1 (des-Boc pyrrolidine) and M2 (iodo regioisomer) to be limited to <0.10% and <0.15%, respectively, verified by UPLC-MS with a 1.7 µm C18 column.

An emerging segment that utilizes the Boc-aminophenylpyrrolidine in a solid-phase peptide synthesis (SPPS) context has gained traction for constructing macrocyclic peptides with improved cellular permeability. In this protocol, the Boc-protected aniline is first coupled with Fmoc-Glu(OtBu)-OH via HOBt/DIC activation in DMF, then loaded onto 2-chlorotrityl chloride resin (loading 0.8 mmol/g). After iterative Fmoc SPPS elongation, the N-terminal Boc group is removed with TFA/TIS/H₂O 95:2.5:2.5 (v/v/v), liberating the aliphatic pyrrolidine nitrogen for on-resin cyclization via a C-terminal side-chain anchor. The macrocyclization employs PyBOP (3.0 equiv) and DIPEA (6.0 equiv) in NMP, with a monitored completion by Kaiser test. Cleavage from the resin and global deprotection yields a crude cyclic peptide that exhibits a PAMPA permeability coefficient exceeding 15 × 10⁻⁶ cm/s at pH 7.4, compared to sub-1.0 × 10⁻⁶ cm/s for the linear precursor. The 2-(2-aminophenyl)pyrrolidine element introduces a kink in the macrocyclic backbone that shifts the TPSA below 140 Ų, an empirical threshold for oral absorption. Published data for this specific resin-bound cyclization remain sparse; however, internal process development reports from a Geneva-based peptide CMO document a batch-to-batch DKP formation risk of 2–4% when the deprotected pyrrolidine nitrogen is exposed to the activated ester for extended periods (> 2 h), controlled by using a segmented flow microreactor (Corning Advanced-Flow G1) that reduces the residence time to 45 seconds. All operations involving TFA cleavage are conducted in walk-in fume hoods rated for 0.3 m/s face velocity, and waste cyanide-laced scavenger mixtures are neutralized per local environmental permits. The target product class encompasses oral somatostatin receptor 2 agonists and constrained PCSK9 ligand peptides currently in Phase I clinical evaluation.